523 related articles for article (PubMed ID: 30195238)
1. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
Granchi C
Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
[TBL] [Abstract][Full Text] [Related]
2. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
[TBL] [Abstract][Full Text] [Related]
3. ATP citrate lyase inhibitors as novel cancer therapeutic agents.
Zu XY; Zhang QH; Liu JH; Cao RX; Zhong J; Yi GH; Quan ZH; Pizzorno G
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):154-67. PubMed ID: 22339355
[TBL] [Abstract][Full Text] [Related]
4. ATP citrate lyase: A central metabolic enzyme in cancer.
Icard P; Wu Z; Fournel L; Coquerel A; Lincet H; Alifano M
Cancer Lett; 2020 Feb; 471():125-134. PubMed ID: 31830561
[TBL] [Abstract][Full Text] [Related]
5. ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch.
Zhao S; Torres A; Henry RA; Trefely S; Wallace M; Lee JV; Carrer A; Sengupta A; Campbell SL; Kuo YM; Frey AJ; Meurs N; Viola JM; Blair IA; Weljie AM; Metallo CM; Snyder NW; Andrews AJ; Wellen KE
Cell Rep; 2016 Oct; 17(4):1037-1052. PubMed ID: 27760311
[TBL] [Abstract][Full Text] [Related]
6. An allosteric mechanism for potent inhibition of human ATP-citrate lyase.
Wei J; Leit S; Kuai J; Therrien E; Rafi S; Harwood HJ; DeLaBarre B; Tong L
Nature; 2019 Apr; 568(7753):566-570. PubMed ID: 30944472
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
Migita T; Okabe S; Ikeda K; Igarashi S; Sugawara S; Tomida A; Soga T; Taguchi R; Seimiya H
Int J Cancer; 2014 Jul; 135(1):37-47. PubMed ID: 24310723
[TBL] [Abstract][Full Text] [Related]
8. ATP-citrate lyase: a key player in cancer metabolism.
Zaidi N; Swinnen JV; Smans K
Cancer Res; 2012 Aug; 72(15):3709-14. PubMed ID: 22787121
[TBL] [Abstract][Full Text] [Related]
9. ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective.
Granchi C
Expert Opin Ther Pat; 2022 Jul; 32(7):731-742. PubMed ID: 35436171
[TBL] [Abstract][Full Text] [Related]
10. Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases.
Liang JJ; Zhou XF; Long H; Li CY; Wei J; Yu XQ; Guo ZY; Zhou YQ; Deng ZS
Bioorg Chem; 2024 Jan; 142():106933. PubMed ID: 37890210
[TBL] [Abstract][Full Text] [Related]
11. ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway.
Lee JH; Jang H; Lee SM; Lee JE; Choi J; Kim TW; Cho EJ; Youn HD
FEBS J; 2015 Jan; 282(2):361-71. PubMed ID: 25367309
[TBL] [Abstract][Full Text] [Related]
12. Polyamine regulating protein antizyme binds to ATP citrate lyase to accelerate acetyl-CoA production in cancer cells.
Tajima A; Murai N; Murakami Y; Iwamoto T; Migita T; Matsufuji S
Biochem Biophys Res Commun; 2016 Mar; 471(4):646-51. PubMed ID: 26915799
[TBL] [Abstract][Full Text] [Related]
13. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
Shah S; Carriveau WJ; Li J; Campbell SL; Kopinski PK; Lim HW; Daurio N; Trefely S; Won KJ; Wallace DC; Koumenis C; Mancuso A; Wellen KE
Oncotarget; 2016 Jul; 7(28):43713-43730. PubMed ID: 27248322
[TBL] [Abstract][Full Text] [Related]
14. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms.
Zaidi N; Royaux I; Swinnen JV; Smans K
Mol Cancer Ther; 2012 Sep; 11(9):1925-35. PubMed ID: 22718913
[TBL] [Abstract][Full Text] [Related]
15. ATP-citrate lyase multimerization is required for coenzyme-A substrate binding and catalysis.
Bazilevsky GA; Affronti HC; Wei X; Campbell SL; Wellen KE; Marmorstein R
J Biol Chem; 2019 May; 294(18):7259-7268. PubMed ID: 30877197
[TBL] [Abstract][Full Text] [Related]
16. Targeting mitochondrial citrate transport in breast cancer cell lines.
Ozkaya AB; Ak H; Atay S; Aydin HH
Anticancer Agents Med Chem; 2015; 15(3):374-81. PubMed ID: 25511512
[TBL] [Abstract][Full Text] [Related]
17. Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase.
Ismail A; Doghish AS; E M Elsadek B; Salama SA; Mariee AD
Steroids; 2020 Aug; 160():108656. PubMed ID: 32439410
[TBL] [Abstract][Full Text] [Related]
18. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
Guo L; Guo YY; Li BY; Peng WQ; Chang XX; Gao X; Tang QQ
J Biol Chem; 2019 Aug; 294(31):11805-11816. PubMed ID: 31197036
[TBL] [Abstract][Full Text] [Related]
19. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
20. Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase.
Namgaladze D; Zukunft S; Schnütgen F; Kurrle N; Fleming I; Fuhrmann D; Brüne B
Front Immunol; 2018; 9():2858. PubMed ID: 30568658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
